Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study

Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study

Summary: Background: In the global REACH-2 study, ramucirumab significantly improved overall survival (OS) compared with placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). REACH-2 China study aimed to evaluate the efficacy and safety of ramuciruma...

Full description

Bibliographic Details
Main Authors: Guoliang Shao, Yuxian Bai, Xianglin Yuan, Xiaomin Chen, Shanzhi Gu, Kangsheng Gu, Chunhong Hu, Houjie Liang, Yabing Guo, Jufeng Wang, Chia-Jui Yen, Victor Ho-Fun Lee, Chunxiao Wang, Ryan C. Widau, Wanli Zhang, Junjun Liu, Qiang Zhang, Shukui Qin
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:EClinicalMedicine
Subjects:
Ramucirumab
Second-line therapy
Advanced hepatocellular carcinoma
Phase 3 study
China
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022004096

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022004096

Similar Items